

392

European Medicines Agency  
Domenico Scarlattilaan 6,  
1083 HS Amsterdam

**Radboud university medical center**  
Radboudumc Technology Center Clinical Studies

P.O. Box 9101, 6500 HB Nijmegen  
The Netherlands  
Internal postal code 392  
Philips van Leydenlaan 15  
Radboudumc entrance west, route 392  
T +31 24 366 83 33

Manager Policy, Quality and Support  
mrs. J.A.H. Droste, PhD  
rtclinicalstudies@radboudumc.nl  
www.radboudumc.nl

Date	Our reference	Page
6 July 2022	AN/JdH	1 of 1

Your reference	Contact RTC Clinical Studies rtclinicalstudies@radboudumc.nl
----------------	--

Dutch Chamber of Commerce  
trade register 80262783

**Subject**

Results posting of 2009-011906-40; The use of antibiotics in therapy resistant Lichen Sclerosus patients

Dear EMA,

On behalf of dr Joanne de Hullu (gynecologic oncologist) as the PI of this study, I hereby confirm that the inclusion of subjects in the following clinical trial protocol: "The use of antibiotics in therapy resistant Lichen Sclerosus patients" with EudraCT number **2009-011906-40**, had been prematurely ended on April 1<sup>st</sup> 2010. Four subjects have been treated according to protocol.

The reason for early termination is futility, since antibiotic treatment with benzathinebenzylpenicilline in addition to standard therapy with ultrapotent corticosteroids did not result in significant clinical improvement. Of the 4 subjects that were treated according to the study protocol, no additional side effects have been reported.

We hope this information is satisfactory to finalize results posting in EudraCT.

With kind regards,

Arjan Nootboom,  
Research Consultant at RTC Clinical Studies  
Radboudumc  
[rtclinicalstudies@radboudumc.nl](mailto:rtclinicalstudies@radboudumc.nl)

cc dr Joanne de Hullu, gynecologic oncologist